Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals Inc is anticipated to experience significant revenue growth, particularly from its product Khindivi, with projections estimating an increase from $3 million in 2025 to a peak of $28 million by 2030. The company has raised the probability of Khindivi's launch to 100%, coupled with an adjustment for an earlier launch in June 2025 and an increase in expected market penetration from 40% to 60% due to the product's ease of administration. Given the demonstrated strength of management in commercial execution, 2025 is expected to be a pivotal year for revenue inflection for the company.

Bears say

Eton Pharmaceuticals's stock outlook appears negative primarily due to the high discount rate of 11% applied in the financial analysis, which indicates a cautious approach towards the company's future cash flows. Additionally, the modest terminal growth rate of 2% further suggests a limited potential for sustained long-term revenue growth, raising concerns about the company’s ability to meet market expectations. Despite a slight increase in the 12-month price target to $35 per diluted share, the fundamental assumptions reflect a cautious stance that may impact investor confidence moving forward.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.